| Post | Subject | | |
#214481
|
Risk of Death Persists for Years after Hip Fracture
|
Titan V
| 10/21/17 12:44:19 PM |
|
#214478
|
From PR: However, the primary endpoint, which evaluates
|
iwfal
| 10/20/17 09:20:13 PM |
|
#214475
|
AGEN—+17%/AH—on FDA approval of GSK’s Shingrix shingles vaccine,
|
DewDiligence
| 10/20/17 08:24:37 PM |
|
#214469
|
ABEO:
At the R&D Day the MPS presenter said
|
ghmm
| 10/20/17 03:16:49 PM |
|
#214359
|
IMDX -19%—my take from today’s CC…
|
DewDiligence
| 10/17/17 03:19:07 PM |
|
#213801
|
Re: Buying in advance of phase-3
|
DewDiligence
| 09/23/17 02:15:40 PM |
|
#214482
|
Liquidation fund distribution, an example (off topic)
|
dangerM
| 10/21/17 05:53:58 PM |
|
#214481
|
Risk of Death Persists for Years after Hip Fracture
|
Titan V
| 10/21/17 12:44:19 PM |
|
#214480
|
DBVT Even if ultimately approved, how much has
|
iwfal
| 10/21/17 11:54:20 AM |
|
#214479
|
DBVT - All told I think it would
|
mcbio
| 10/21/17 10:22:43 AM |
|
#214478
|
From PR: However, the primary endpoint, which evaluates
|
iwfal
| 10/20/17 09:20:13 PM |
|
#214477
|
FWIW, I add more today and already have
|
kris_kade
| 10/20/17 09:12:19 PM |
|
#214476
|
ATRS receives CRL for Xyosted:
|
DewDiligence
| 10/20/17 08:54:11 PM |
|
#214475
|
AGEN—+17%/AH—on FDA approval of GSK’s Shingrix shingles vaccine,
|
DewDiligence
| 10/20/17 08:24:37 PM |
|
#214474
|
trxc - CEO exercised 0.35 options sells 600K
|
nowlurking
| 10/20/17 07:28:00 PM |
|
#214473
|
From same DBVT—(-60%/AH)—PR: DBV Technologies…today announced topline results
|
DewDiligence
| 10/20/17 04:59:34 PM |
|
#214472
|
DBVT fails https://media.dbv-technologies.com/d286/ressources/_pdf/5/4257-PR-PEP
|
ronpopeil
| 10/20/17 04:57:21 PM |
|
#214471
|
hey i am adding lol, not kidding either.
|
linhdtu
| 10/20/17 03:56:47 PM |
|
#214470
|
GILD and ABBV lobbying for stupidity? Just kidding
|
rkrw
| 10/20/17 03:36:11 PM |
|
#214469
|
ABEO:
At the R&D Day the MPS presenter said
|
ghmm
| 10/20/17 03:16:49 PM |
|
#214468
|
RVNC has always been a volatile stock. I
|
DewDiligence
| 10/20/17 02:56:12 PM |
|
#214467
|
RVNC down $.40~$.50 per day rather consistently over
|
biotech_researcher
| 10/20/17 02:46:54 PM |
|
#214466
|
Re: CELG
|
ciotera
| 10/20/17 01:45:23 PM |
|
#214465
|
“CVS is going to be under considerable pressure
|
biotech_researcher
| 10/20/17 01:34:35 PM |
|
#214464
|
CXRX -33% on plan to "realign...capital structure":
|
DewDiligence
| 10/20/17 01:34:31 PM |
|
#214463
|
ABEO ...PPS rises following $92 m offering
|
Whalatane
| 10/20/17 12:43:08 PM |
|
#214462
|
>$10B NPV?
|
DewDiligence
| 10/20/17 12:04:01 PM |
|
#214461
|
Re: CELG
|
ciotera
| 10/20/17 12:02:45 PM |
|
#214460
|
DRRX -60% on phase-3 failure of Posimir in
|
DewDiligence
| 10/20/17 11:36:40 AM |
|
#214459
|
CELG -10%—(>$10B market-cap reduction)—on GED-0301 termination. Evidently, some
|
DewDiligence
| 10/20/17 11:27:37 AM |
|
#214458
|
ENTA—Mavyret scripts for week ending 10/13/17 (according to
|
DewDiligence
| 10/20/17 10:34:37 AM |
|
#214457
|
RXDX sells 11.5M* shares @$16.00—a 1.5% discount to
|
DewDiligence
| 10/19/17 08:42:15 PM |
|
#214456
|
Oh ok thanks. So adhd will be about
|
camacho
| 10/19/17 08:33:16 PM |
|
#214455
|
ADHD’s share count will increase by 150% when
|
DewDiligence
| 10/19/17 08:24:41 PM |
|
#214454
|
Dew, does the reverse merger increase the current
|
camacho
| 10/19/17 08:06:47 PM |
|
#214453
|
Yes it does. On balance there isn't
|
n4807g
| 10/19/17 07:56:54 PM |
|
#214452
|
Recent Biotech Buyouts of Publicly Traded Companies
|
DewDiligence
| 10/19/17 07:06:31 PM |
|
#214451
|
IMDZ ...yep ...don't mess with Dew ...:-) .
|
Whalatane
| 10/19/17 06:47:57 PM |
|
#214450
|
It's unlikely that AGN would split in such
|
DewDiligence
| 10/19/17 06:35:56 PM |
|
#214449
|
(RVNC) - Allergan's stock-price struggles sure to trigger
|
Bickema
| 10/19/17 06:25:03 PM |
|
#214448
|
RE ADHD yes but it does make a
|
mazlat10
| 10/19/17 06:13:20 PM |
|
#214447
|
Thanks much re ADHD
|
mazlat10
| 10/19/17 06:10:45 PM |
|
#214446
|
IMDZ -50% on the week (eom).
|
DewDiligence
| 10/19/17 05:21:35 PM |
|
#214445
|
Oops!
|
DewDiligence
| 10/19/17 05:16:08 PM |
|
#214444
|
Good news for CELG: They won't have to
|
DewDiligence
| 10/19/17 05:14:30 PM |
|
#214443
|
CELG discontinues GED-0301 (mongersen) IBD program following futility
|
DewDiligence
| 10/19/17 04:48:08 PM |
|
#214442
|
Re: UV/blue-light emissions from consumer devices
|
DewDiligence
| 10/19/17 03:20:00 PM |
|
#214441
|
Is that important?
|
n4807g
| 10/19/17 02:27:58 PM |
|
#214440
|
Arcturus is still private (until the reverse-merger with
|
DewDiligence
| 10/19/17 02:15:16 PM |
|
#214439
|
RE ADHD Why no mention of how much
|
mazlat10
| 10/19/17 02:07:37 PM |
|
#214438
|
TYME (f/k/a TYMI) data dredging lifts stock 6%:
|
DewDiligence
| 10/19/17 01:46:29 PM |
|
#214437
|
CNCE +10% on denial of INCY’s IPR petition
|
DewDiligence
| 10/19/17 01:41:51 PM |
|
#214436
|
GLMD “NASH KOL” webcast 10/26/17:
|
DewDiligence
| 10/19/17 01:37:15 PM |
|
#214435
|
liking his "definitely"
|
ash111
| 10/19/17 01:10:20 PM |
|
#214434
|
CVS is going to be under considerable pressure
|
willyw
| 10/19/17 01:09:11 PM |
|
#214433
|
ONCS +13%, Adam F. "Right now, updated data
|
ash111
| 10/19/17 01:06:40 PM |
| Post | Subject | | |